• Home
• Faculty
• Refer a Colleague
• Sign-up for E-mail Updates

If you attended the symposium held December 7, 2010, during the 45th ASHP Midyear Clinical Meeting and Exhibition in person or via webcast (2 hours CPE), use the links below to download the handout and process your CPE.

• Handout for Symposium
• CPE Processing Instructions
  
  • Anaheim Participants
    
  • Webcast Participants

This educational initiative focuses on issues related to optimizing the use of oral antiplatelet therapy in patients with acute coronary syndrome. Despite recent advances in the treatment of acute coronary syndrome (ACS), mortality associated with both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) remains unacceptably high. Patients who experience an acute myocardial infarction are at increased risk for future coronary episodes, and mortality increases with subsequent events. While the need for dual antiplatelet therapy in patients with ACS is well established, pharmacists are met with many clinical dilemmas as they seek to optimize therapy, such as the duration of oral antiplatelet therapy, clopidogrel nonresponsiveness, and laboratory testing of platelet reactivity and patient genotypes. New information related to emerging treatment strategies, such as triple antiplatelet therapy and pipeline agents, is also available.

Choose from among the following continuing pharmacy education (CPE) activities and other learning opportunities to expand your knowledge related to optimizing oral antiplatelet therapy in acute coronary syndrome, as well as to learn tips for incorporating that knowledge into practice.